logo
Plus   Neg
Share
Email

Roche Reports Positive Data From OCREVUS Phase III Open-label Extension Studies

Roche (RHHBY.PK) said data from three phase III open-label extension studies demonstrated that patients who were treated with OCREVUS for six years or more had reduced risk of disability progression in relapsing multiple sclerosis and primary progressive multiple sclerosis. The company said the results show earlier treatment with OCREVUS reduced the risk of disability progression and the effect was sustained over time.

OCREVUS is the first and only therapy approved for both relapsing multiple sclerosis and primary progressive multiple sclerosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla said it will produce ventilators at its Gigafactory in Buffalo, New York to support the city's hospitals amid the coronavirus pandemic. New York is the worst affected state in the U.S. Last Saturday, Musk tweeted that he "had a long engineering discussion with Medtronic about state-of-the-art ventilators. Luxury fashion house Ralph Lauren will donate $10 million to help fight the coronavirus pandemic and manufacture face masks as well as medical gowns in the U.S. The company's charity arm, the Ralph Lauren Corporate Foundation, said in a statement that it is committing $10 million towards the global response to the COVID-19 pandemic. General Motors Co. is delaying work on new vehicle models and is cutting pay for its executives as part of efforts to conserve cash amid the coronavirus or Covid-19 pandemic. The automotive giant also extended the shutdown of North American plants indefinitely. Multiple reports cited an internal memo that salaried workforce will have 20 percent of pay deferred starting April 1.
Follow RTT
>